NASDAQ:SNSE Sensei Biotherapeutics Q4 2024 Earnings Report $17.56 -0.02 (-0.11%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$17.75 +0.19 (+1.08%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sensei Biotherapeutics EPS ResultsActual EPS-$5.40Consensus EPS -$5.40Beat/MissMet ExpectationsOne Year Ago EPSN/ASensei Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASensei Biotherapeutics Announcement DetailsQuarterQ4 2024Date3/28/2025TimeBefore Market OpensConference Call DateFriday, March 28, 2025Conference Call Time7:30AM ETUpcoming EarningsSensei Biotherapeutics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Sensei Biotherapeutics Earnings HeadlinesInsider Buying: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Acquires $246,523.38 in StockMay 18, 2026 | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Acquires $164,021.22 in StockMay 18, 2026 | americanbankingnews.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 22 at 1:00 AM | Porter & Company (Ad)Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells $246,231.92 in StockMay 18, 2026 | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $407,691.81 in StockMay 18, 2026 | americanbankingnews.comInsider Buying: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Buys $212,975.75 in StockMay 18, 2026 | americanbankingnews.comSee More Sensei Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email. Email Address About Sensei BiotherapeuticsSensei Biotherapeutics (NASDAQ:SNSE) is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies. The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways. In addition to these clinical-stage candidates, Sensei is advancing preclinical projects against novel innate immune checkpoints and exploring combination regimens to broaden therapeutic impact. Founded in 2018 and headquartered in Cambridge, Massachusetts, Sensei Biotherapeutics operates across the United States and collaborates with academic and industry partners to accelerate research and development. The company’s leadership team brings extensive experience in antibody therapeutics, translational research and clinical development, supporting its mission to bring innovative immunotherapies through clinical trials and deliver new treatment options for patients worldwide.View Sensei Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue Growth Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
